{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T12:21:21Z","timestamp":1756902081071,"version":"3.44.0"},"reference-count":24,"publisher":"The Pediatric Pharmacy Association","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"abstract":"<jats:sec>\n          <jats:title>OBJECTIVE<\/jats:title>\n          <jats:p>Daptomycin is a lipopeptide antibiotic with rapid bactericidal activity against Gram-positive bacteria. Reports regarding the use of daptomycin in infants are still limited. Thus, the objective of this report is to describe the safety and efficacy of daptomycin in premature infants with persistent coagulase-negative staphylococci (CoNS) infection.<\/jats:p>\n        <\/jats:sec>\n        <jats:sec>\n          <jats:title>METHODS<\/jats:title>\n          <jats:p>This was a retrospective chart review of 10 premature infants with persistent CoNS infection who received daptomycin therapy between January 2018 and September 2019. Four patients had endocarditis and 1 had bacterial meningitis and infectious endocarditis. The other 5 patients had persistent CoNS bacteraemia only.<\/jats:p>\n        <\/jats:sec>\n        <jats:sec>\n          <jats:title>RESULTS<\/jats:title>\n          <jats:p>Daptomycin treatment was successful for 5 patients. The others died owing to multiple factors such as prematurity, sepsis, and chronic lung disease. Adverse drug reactions, including elevation of creatine phosphokinase and\/or hepatotoxicity, were noted in 4 patients.<\/jats:p>\n        <\/jats:sec>\n        <jats:sec>\n          <jats:title>CONCLUSIONS<\/jats:title>\n          <jats:p>Large and randomized studies are necessary to ensure daptomycin's safety and efficacy for the treatment of infants with persistent sepsis caused by Gram-positive bacteria.<\/jats:p>\n        <\/jats:sec>","DOI":"10.5863\/1551-6776-26.1.92","type":"journal-article","created":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T23:36:29Z","timestamp":1609803389000},"page":"92-98","source":"Crossref","is-referenced-by-count":1,"title":["The Use of Daptomycin in the Treatment of Persistent Coagulase-Negative Staphylococcal Sepsis in Premature Infants: A Case Series"],"prefix":"10.5863","volume":"26","author":[{"given":"Suzan S.","family":"Asfour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raneem S.","family":"Asfour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thanaa M.","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mountasser M.","family":"Al-Mouqdad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3883","reference":[{"issue":"2 pt 1","key":"i1551-6776-26-1-92-b1","series-title":"Pediatrics","first-page":"285","article-title":"Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network","volume":"110","year":"2002","unstructured":"Stoll\n              BJ,\n            \n            \n              Hansen\n              N,\n            \n            \n              Fanaroff\n              AA,\n            \n          \n          .\n\t\t\t\t\tLate-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network.\n\t\t\t\t\tPediatrics.\n\t\t\t\t\t2002;\n\t\t\t\t\t110(\n\t\t\t\t\t2 pt 1):\n\t\t\t\t\t285\u2013\n\t\t\t\t\t291."},{"issue":"3","key":"i1551-6776-26-1-92-b2","series-title":"J Clin Neonatol","first-page":"141","article-title":"A retrospective cohort study patient chart review of neonatal sepsis investigating responsible microorganisms and their antimicrobial susceptibility","volume":"7","year":"2018","unstructured":"Al-Mouqdad\n              MM,\n            \n            \n              Alaklobi\n              FA,\n            \n            \n              Aljobair\n              FH,\n            \n          \n          .\n\t\t\t\t\tA retrospective cohort study patient chart review of neonatal sepsis investigating responsible microorganisms and their antimicrobial susceptibility.\n\t\t\t\t\tJ Clin Neonatol.\n\t\t\t\t\t2018;\n\t\t\t\t\t7(\n\t\t\t\t\t3):\n\t\t\t\t\t141\u2013\n\t\t\t\t\t145."},{"issue":"6","key":"i1551-6776-26-1-92-b3","series-title":"Eur J Clin Microbiol Infect Dis","first-page":"403","article-title":"Glycopeptide resistance in coagulase-negative staphylococci","volume":"19","year":"2000","unstructured":"Biavasco\n              F,\n            \n            \n              Vignaroli\n              C,\n            \n            \n              Varaldo\n              PE.\n            \n          \n          Glycopeptide resistance in coagulase-negative staphylococci.\n\t\t\t\t\tEur J Clin Microbiol Infect Dis.\n\t\t\t\t\t2000;\n\t\t\t\t\t19(\n\t\t\t\t\t6):\n\t\t\t\t\t403\u2013\n\t\t\t\t\t417."},{"issue":"2","key":"i1551-6776-26-1-92-b4","series-title":"Int J Antimicrob Agents","first-page":"106","article-title":"Linezolid treatment of nosocomial bacterial infection with multiresistant Gram-positive pathogens in preterm infants: a systematic review","volume":"36","year":"2010","unstructured":"Kocher\n              SW,\n            \n            \n              Muller\n              W,\n            \n            \n              Resch\n              B.\n            \n          \n          Linezolid treatment of nosocomial bacterial infection with multiresistant Gram-positive pathogens in preterm infants: a systematic review.\n\t\t\t\t\tInt J Antimicrob Agents.\n\t\t\t\t\t2010;\n\t\t\t\t\t36(\n\t\t\t\t\t2):\n\t\t\t\t\t106\u2013\n\t\t\t\t\t110."},{"issue":"3","key":"i1551-6776-26-1-92-b5","series-title":"J Antimicrob Chemother","first-page":"643","article-title":"Daptomycin in paediatrics: current knowledge and the need for future research","volume":"70","year":"2015","unstructured":"Principi\n              N,\n            \n            \n              Caironi\n              M,\n            \n            \n              Venturini\n              F,\n            \n          \n          .\n\t\t\t\t\tDaptomycin in paediatrics: current knowledge and the need for future research.\n\t\t\t\t\tJ Antimicrob Chemother.\n\t\t\t\t\t2015;\n\t\t\t\t\t70(\n\t\t\t\t\t3):\n\t\t\t\t\t643\u2013\n\t\t\t\t\t648."},{"key":"i1551-6776-26-1-92-b6","unstructured":"Insert, Package. \u201cCubicin (daptomycin for injection). Lexington MA.(Cubist Pharmaceuticals, Inc).\u201d (2008)."},{"issue":"1","key":"i1551-6776-26-1-92-b7","series-title":"J Pediatr Neonat Individual Med","doi-asserted-by":"publisher","first-page":"e080109","DOI":"10.7363\/080109","article-title":"Successful treatment of Staphylococcus haemolyticus endocarditis in extremely premature baby with daptomycin","volume":"8","year":"2019","unstructured":"Asfour\n              SS,\n            \n            \n              Aljobair\n              F,\n            \n            \n              Hammami\n              I,\n            \n          \n          .\n\t\t\t\t\tSuccessful treatment of Staphylococcus haemolyticus endocarditis in extremely premature baby with daptomycin.\n\t\t\t\t\tJ Pediatr Neonat Individual Med.\n\t\t\t\t\t2019;\n\t\t\t\t\t8(\n\t\t\t\t\t1):\n\t\t\t\t\te080109.\n\t\t\t\t\tdoi:10.7363\/080109"},{"issue":"3","key":"i1551-6776-26-1-92-b8","series-title":"J Perinatol","first-page":"233","article-title":"Daptomycin use in infants: report of two cases with peak and trough drug concentrations","volume":"28","year":"2008","unstructured":"Cohen-Wolkowiez\n              M,\n            \n            \n              Smith\n              PB,\n            \n            \n              Benjamin\n              DK\n              Jr\n            ,\n\t\t\t\t\t\n          .\n\t\t\t\t\tDaptomycin use in infants: report of two cases with peak and trough drug concentrations.\n\t\t\t\t\tJ Perinatol.\n\t\t\t\t\t2008;\n\t\t\t\t\t28(\n\t\t\t\t\t3):\n\t\t\t\t\t233\u2013\n\t\t\t\t\t234."},{"issue":"2","key":"i1551-6776-26-1-92-b9","series-title":"Pediatrics","first-page":"340","article-title":"Persistent bacteremia and severe thrombocytopenia caused by coagulase-negative Staphylococcus in a neonatal intensive care unit","volume":"117","year":"2006","unstructured":"Khashu\n              M,\n            \n            \n              Osiovich\n              H,\n            \n            \n              Henry\n              D,\n            \n          \n          .\n\t\t\t\t\tPersistent bacteremia and severe thrombocytopenia caused by coagulase-negative Staphylococcus in a neonatal intensive care unit.\n\t\t\t\t\tPediatrics.\n\t\t\t\t\t2006;\n\t\t\t\t\t117(\n\t\t\t\t\t2):\n\t\t\t\t\t340\u2013\n\t\t\t\t\t348."},{"issue":"pt 3","key":"i1551-6776-26-1-92-b10","series-title":"J Med Microbiol","first-page":"381","article-title":"Successful treatment of methicillin-resistant Staphylococcus aureus bacteraemia in a neonate using daptomycin","volume":"60","year":"2011","unstructured":"Hussain\n              A,\n            \n            \n              Kairamkonda\n              V,\n            \n            \n              Jenkins\n              DR.\n            \n          \n          Successful treatment of methicillin-resistant Staphylococcus aureus bacteraemia in a neonate using daptomycin.\n\t\t\t\t\tJ Med Microbiol.\n\t\t\t\t\t2011;\n\t\t\t\t\t60(\n\t\t\t\t\tpt 3):\n\t\t\t\t\t381\u2013\n\t\t\t\t\t383."},{"issue":"6","key":"i1551-6776-26-1-92-b11","series-title":"Clin Pharmacol Ther","first-page":"806","article-title":"Case definition and phenotype standardization in drug-induced liver injury","volume":"89","year":"2011","unstructured":"Aithal\n              GP,\n            \n            \n              Watkins\n              PB,\n            \n            \n              Andrade\n              RJ,\n            \n          \n          .\n\t\t\t\t\tCase definition and phenotype standardization in drug-induced liver injury.\n\t\t\t\t\tClin Pharmacol Ther.\n\t\t\t\t\t2011;\n\t\t\t\t\t89(\n\t\t\t\t\t6):\n\t\t\t\t\t806\u2013\n\t\t\t\t\t815."},{"issue":"11","key":"i1551-6776-26-1-92-b12","series-title":"J Clin Epidemiol","first-page":"1323","article-title":"Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries","volume":"46","year":"1993","unstructured":"Danan\n              G,\n            \n            \n              Benichou\n              C.\n            \n          \n          Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries.\n\t\t\t\t\tJ Clin Epidemiol.\n\t\t\t\t\t1993;\n\t\t\t\t\t46(\n\t\t\t\t\t11):\n\t\t\t\t\t1323\u2013\n\t\t\t\t\t1330."},{"issue":"24","key":"i1551-6776-26-1-92-b13","series-title":"Bioorg Med Chem","first-page":"6253","article-title":"The action mechanism of daptomycin","volume":"24","year":"2016","unstructured":"Taylor\n              SD,\n            \n            \n              Palmer\n              M.\n            \n          \n          The action mechanism of daptomycin.\n\t\t\t\t\tBioorg Med Chem.\n\t\t\t\t\t2016;\n\t\t\t\t\t24(\n\t\t\t\t\t24):\n\t\t\t\t\t6253\u2013\n\t\t\t\t\t6268."},{"issue":"12","key":"i1551-6776-26-1-92-b14","series-title":"J Antimicrob Chemother","first-page":"3181","article-title":"Efficacy and safety of daptomycin for the treatment of infectious disease: a meta-analysis based on randomized controlled trials","volume":"69","year":"2014","unstructured":"He\n              W,\n            \n            \n              Wang\n              H.\n            \n          \n          Efficacy and safety of daptomycin for the treatment of infectious disease: a meta-analysis based on randomized controlled trials.\n\t\t\t\t\tJ Antimicrob Chemother.\n\t\t\t\t\t2014;\n\t\t\t\t\t69(\n\t\t\t\t\t12):\n\t\t\t\t\t3181\u2013\n\t\t\t\t\t1389."},{"issue":"2","key":"i1551-6776-26-1-92-b15","series-title":"J Clin Microbiol","first-page":"595","article-title":"Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis","volume":"44","year":"2006","unstructured":"Marty\n              FM,\n            \n            \n              Yeh\n              WW,\n            \n            \n              Wennersten\n              CB,\n            \n          \n          .\n\t\t\t\t\tEmergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis.\n\t\t\t\t\tJ Clin Microbiol.\n\t\t\t\t\t2006;\n\t\t\t\t\t44(\n\t\t\t\t\t2):\n\t\t\t\t\t595\u2013\n\t\t\t\t\t597."},{"issue":"6","key":"i1551-6776-26-1-92-b16","series-title":"J Infect","first-page":"567","article-title":"Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients","volume":"54","year":"2007","unstructured":"Poutsiaka\n              DD,\n            \n            \n              Skiffington\n              S,\n            \n            \n              Miller\n              KB,\n            \n          \n          .\n\t\t\t\t\tDaptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients.\n\t\t\t\t\tJ Infect.\n\t\t\t\t\t2007;\n\t\t\t\t\t54(\n\t\t\t\t\t6):\n\t\t\t\t\t567\u2013\n\t\t\t\t\t571."},{"issue":"4","key":"i1551-6776-26-1-92-b17","series-title":"J Pediatric Infect Dis Soc","first-page":"446","article-title":"Clinical effectiveness, safety profile, and pharmacokinetics of daptomycin in pediatric patients: a systematic review","volume":"5","year":"2016","unstructured":"Karageorgos\n              SA,\n            \n            \n              Miligkos\n              M,\n            \n            \n              Dakoutrou\n              M,\n            \n            \n              Tsioutis\n              C.\n            \n          \n          Clinical effectiveness, safety profile, and pharmacokinetics of daptomycin in pediatric patients: a systematic review.\n\t\t\t\t\tJ Pediatric Infect Dis Soc.\n\t\t\t\t\t2016;\n\t\t\t\t\t5(\n\t\t\t\t\t4):\n\t\t\t\t\t446\u2013\n\t\t\t\t\t457."},{"key":"i1551-6776-26-1-92-b18","series-title":"BMC Pediatr","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1471-2431-10-84","article-title":"Use of rifampin in persistent coagulase negative staphylococcal bacteremia in neonates","volume":"10","year":"2010","unstructured":"van der Lugt\n              NM,\n            \n            \n              Steggerda\n              SJ,\n            \n            \n              Walther\n              FJ.\n            \n          \n          Use of rifampin in persistent coagulase negative staphylococcal bacteremia in neonates.\n\t\t\t\t\tBMC Pediatr.\n\t\t\t\t\t2010;\n\t\t\t\t\t10:\n\t\t\t\t\t84.\n\t\t\t\t\tdoi:10.1186\/1471-2431-10-84"},{"issue":"5","key":"i1551-6776-26-1-92-b19","series-title":"Eur J Pediatr","first-page":"693","article-title":"Combination of vancomycin and rifampin for the treatment of persistent coagulase-negative staphylococcal bacteremia in preterm neonates","volume":"172","year":"2013","unstructured":"Rodriguez-Guerineau\n              L,\n            \n            \n              Salvia-Roig\u00e9s\n              MD,\n            \n            \n              Le\u00f3n-Lozano\n              M,\n            \n          \n          .\n\t\t\t\t\tCombination of vancomycin and rifampin for the treatment of persistent coagulase-negative staphylococcal bacteremia in preterm neonates.\n\t\t\t\t\tEur J Pediatr.\n\t\t\t\t\t2013;\n\t\t\t\t\t172(\n\t\t\t\t\t5):\n\t\t\t\t\t693\u2013\n\t\t\t\t\t697."},{"issue":"suppl 3","key":"i1551-6776-26-1-92-b20","series-title":"Rev Infect Dis","first-page":"S407","article-title":"Rifampin: mechanisms of action and resistance","volume":"5","year":"1983","unstructured":"Wehrli\n              W.\n            \n          \n          Rifampin: mechanisms of action and resistance.\n\t\t\t\t\tRev Infect Dis.\n\t\t\t\t\t1983;\n\t\t\t\t\t5(\n\t\t\t\t\tsuppl 3):\n\t\t\t\t\tS407\u2013\n\t\t\t\t\tS411."},{"issue":"9 suppl","key":"i1551-6776-26-1-92-b21","series-title":"Pediatr Infect Dis J","first-page":"S158","article-title":"Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates","volume":"22","year":"2003","unstructured":"Deville\n              JG,\n            \n            \n              Adler\n              S,\n            \n            \n              Azimi\n              PH,\n            \n          \n          .\n\t\t\t\t\tLinezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates.\n\t\t\t\t\tPediatr Infect Dis J.\n\t\t\t\t\t2003;\n\t\t\t\t\t22(\n\t\t\t\t\t9 suppl):\n\t\t\t\t\tS158\u2013\n\t\t\t\t\tS163."},{"issue":"1","key":"i1551-6776-26-1-92-b22","series-title":"Clin Ther","first-page":"66","article-title":"Clinical efficacy and tolerability of linezolid in pediatric patients: a systematic review","volume":"32","year":"2010","unstructured":"Chiappini\n              E,\n            \n            \n              Conti\n              C,\n            \n            \n              Galli\n              L,\n            \n            \n              Martino\n              M.\n            \n          \n          Clinical efficacy and tolerability of linezolid in pediatric patients: a systematic review.\n\t\t\t\t\tClin Ther.\n\t\t\t\t\t2010;\n\t\t\t\t\t32(\n\t\t\t\t\t1):\n\t\t\t\t\t66\u2013\n\t\t\t\t\t88."},{"issue":"4","key":"i1551-6776-26-1-92-b23","series-title":"Drugs","first-page":"815","article-title":"Linezolid","volume":"59","year":"2000","unstructured":"Clemett\n              D,\n            \n            \n              Markham\n              A.\n            \n          \n          Linezolid.\n\t\t\t\t\tDrugs.\n\t\t\t\t\t2000;\n\t\t\t\t\t59(\n\t\t\t\t\t4):\n\t\t\t\t\t815\u2013\n\t\t\t\t\t827;\n\t\t\t\t\tdiscussion 828."},{"issue":"10","key":"i1551-6776-26-1-92-b24","series-title":"J Clin Microbiol","first-page":"4660","article-title":"Decreased vancomycin susceptibility of coagulase-negative staphylococci in a neonatal intensive care unit: evidence of spread of Staphylococcus warneri","volume":"41","year":"2003","unstructured":"Center\n              KJ,\n            \n            \n              Reboli\n              AC,\n            \n            \n              Hubler\n              R,\n            \n          \n          .\n\t\t\t\t\tDecreased vancomycin susceptibility of coagulase-negative staphylococci in a neonatal intensive care unit: evidence of spread of Staphylococcus warneri.\n\t\t\t\t\tJ Clin Microbiol.\n\t\t\t\t\t2003;\n\t\t\t\t\t41(\n\t\t\t\t\t10):\n\t\t\t\t\t4660\u2013\n\t\t\t\t\t4665."}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/26\/1\/article-p92.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/meridian.allenpress.com\/jppt\/article-pdf\/26\/1\/92\/2697530\/i1551-6776-26-1-92.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/26\/1\/article-p92.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/26\/1\/article-p92.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:43:47Z","timestamp":1747356227000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/26\/1\/article-p92.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":24,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-26.1.92","relation":{},"ISSN":["1551-6776"],"issn-type":[{"type":"print","value":"1551-6776"}],"subject":[],"published":{"date-parts":[[2021]]}}}